Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Humacyte, Inc. Director's Dealing 2025

Nov 17, 2025

33410_dirs_2025-11-17_b7c5de86-4821-44c1-b841-62290f5e7ed8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2025-11-16

Reporting Person: Sander Dale A. (CFO and Chief Corp. Deve. Off.)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-11-16 Common Stock A 311100 Acquired 313100 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 40600 Indirect

Footnotes

F1: The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The first 50% of the RSUs will vest on May 15, 2026, after which the remaining 50% of the RSUs will vest on May 15, 2027.